Home / Top News / HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts Acadia Pharmaceuticals (ACAD) Investors to Securities Class Action and Application Deadline, Encourages Investors with Losses to Contact Its Attorneys Now
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts Acadia Pharmaceuticals (ACAD) Investors to Securities Class Action and Application Deadline, Encourages Investors with Losses to Contact Its Attorneys Now
SAN FRANCISCO, May 03, 2021 (GLOBE NEWSWIRE) Hagens Berman urges Acadia Pharmaceuticals Inc.
(NASDAQ: ACAD) investors with significant losses to submit your losses now.
Class Period: June 15, 2020 – Apr. 4, 2021
Lead Plaintiff Deadline: June 18, 2021
Visit: www.hbsslaw.com/investor-fraud/ACAD
844-916-0895
Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) Securities Fraud Action:
Share this article
Share this article
LOS ANGELES, May 4, 2021 /PRNewswire/ The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or otherwise acquired Acadia Pharmaceuticals Inc. ( Acadia or the Company ) (NASDAQ: ACAD) securities between
June 15, 2020 and April 4, 2021, inclusive (the Class Period ). Acadia investors have until
June 18, 2021 to file a lead plaintiff motion.
If you are a shareholder who suffered a loss, click here to participate.
Acadia is a biopharmaceutical company that develops a drug called pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia, as well as an adjunctive treatment for major depressive disorder. In June 2020, Acadia submitted a supplemental New Drug Application ( sNDA ) with the U.S. Food and Drug Administration ( FDA ) to expand pimavanserin s label to include treatment for dementia-related psychosis.
NEW YORK, NY / ACCESSWIRE / May 4, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court.
The Law Offices of Frank R Cruz Announces the Filing of a Securities Class Action on Behalf of Acadia Pharmaceuticals Inc (ACAD) Investors prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
NEW YORK, May 2, 2021 /PRNewswire/ Pomerantz LLP announces that a class action lawsuit has been filed against Acadia Pharmaceuticals Inc. ( Acadia or the Company )(NASDAQ: ACAD) and certain of its officers. The class action, filed in the United States District Court for the Southern District of California, and docketed under 21-cv-00762, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Acadia securities between June 15, 2020 and April 4, 2021, both dates inclusive (the Class Period ), seeking to recover damages caused by Defendants violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the Exchange Act ) and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.